logo
Plus   Neg
Share
Email

Anheuser-Busch InBev Announces Changes To Its Board

Anheuser-Busch InBev (BUD) announced changes to its Board of Directors, subject to approval at its annual ordinary and extraordinary shareholders' meeting to be held on 24 April 2019.

Olivier Goudet, Alexandre Behring, Stéfan Descheemaeker and Carlos Alberto Sicupira will be leaving their positions as members of the Board of Directors, immediately after the Annual Shareholders' Meeting. Goudet has served on our Board of Directors since April 2011 and has been its Chairperson since April 2015.

Behring, Descheemaeker and Sicupira have served on Board of Directors since 2014, 2008 and 2004, respectively.

To replace Goudet as Chairperson of Board, the company said it has approached Martin J. Barrington. He will be proposed as the unanimous choice of Board of Directors, including independent directors, as new Chairperson, effective as from the Annual Shareholders' Meeting. Mr. Barrington knows our industry and our company well.

Barrington has been fully retired from his previous role as Chairman and CEO for almost a year and has the time required as Chairperson of Board to dedicate to AB InBev.

To fill the independent director seat left by Goudet, the company proposed Dr. Xiaozhi Liu. To replace Mr. Behring, Mr. Descheemaeker and Mr. Sicupira, our controlling shareholders are pleased to announce that Mr. Claudio Garcia, Ms. Sabine Chalmers and Ms. Cecilia Sicupira, respectively, will be proposed as new directors at the upcoming Annual Shareholders' Meeting.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Twitter Inc. on Friday unlocked the New York Post's Twitter account after a two-week stalemate over posting links to its reporting about Hunter Biden. Walmart has removed guns and ammunition from its store shelves in the U.S. as a precautionary measure following the unrest in Philadelphia after a Black man was fatally shot by police, according to reports. While the firearms will be available for purchase at the Walmart stores, customers will be required to specifically request for them. Regeneron Pharmaceuticals Inc. (REGN) said Friday that the independent data monitoring committee or IDMC for the REGN-COV2 antibody cocktail treatment trials for COVID-19 has recommended to hold further enrollment in hospitalized patients requiring high-flow oxygen or mechanical ventilation.
RELATED NEWS
Follow RTT